Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 7/20 | 0.68 |
| ▸ | TYMP | P19971 | 1/20 | 0.58 |
| ▸ | TYMS | P04818 | 4/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446525 | 1.00 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL3492644 | 1.00 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL3576744 | 1.00 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL10446526 | 1.00 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL3576747 | 1.00 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL19841219 | 0.93 | DUT (0.60) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL14403996 | 0.93 | DUT (0.60) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL13444851 | 0.93 | DUT (0.60) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL3573134 | 0.93 | DUT (0.60) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL912656 | 0.93 | DUT (0.60) | DUTTYMPTYMSP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582748-B2 | efficient synthetic route to an optionally protected 1-halo-2-deoxyribose; formation of an alkyl acetal, such as a methyl acetal, of a furanose, such as 2-deoxyribose, optionally protecting the remaining hydroxyl groups of the furanose, reacting the acetal with an acyl halide that forms the acid halide | MICROBIOLOGICA QUIMICA E FARMACEUTICAL LTD. (BR) | 2009-09-01 | — | — | US | disclosed |
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | DUT, DAO, DCTD | DUT 1/4885TYMP 8/4885TYMS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.